[1]刘秋松,梅雀林,李彦豪,等.化疗栓塞治疗肝癌合并肝动-静脉分流的生存预后因素分析[J].介入放射学杂志,2015,(12):1056-1061.
　LIU Qiu-song,MEI Que-lin,LI Yan-hao,et al.Interventional chemoembolization for the treatment of hepatocellular carcinoma associated with hepatic arteriovenous shunt： analysis of survival prognostic factors[J].journal interventional radiology,2015,(12):1056-1061.
点击复制

化疗栓塞治疗肝癌合并肝动-静脉分流的生存预后因素分析 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2015年12期
页码:
1056-1061
栏目:
肿瘤介入
出版日期:
2015-12-25

文章信息/Info

Title:
Interventional chemoembolization for the treatment of hepatocellular carcinoma associated with hepatic arteriovenous shunt： analysis of survival prognostic factors
作者:
刘秋松;  梅雀林;  李彦豪;  何晓峰;  陈 勇;  曾庆乐;  赵剑波; 王江云;  庞桦进
Author(s):
LIU Qiu-song;  MEI Que-lin;  LI Yan-hao;  HE Xiao-feng;  CHEN Yong;  ZENG Qing-le;  ZHAO Jian-bo;  WANG Jiang-yun;  PANG Hua-jin
Department of Interventional Radiology， Affiliated Nanfang Hospital， Southern Medical University， Guangzhou， Guangdong Province 510515， China
关键词:
【关键词】 聚乙烯醇;  化疗栓塞; 治疗性;  癌; 肝细胞;  肝动静脉分流;  预后因素分析
文献标志码:
A
摘要:
【摘要】 目的 探讨PVA联合碘油化疗药乳剂（或化疗药物）在肝癌合并肝动-静脉分流栓塞治疗的生存预后因素。方法 2013年1月—2014年6月，97例肝癌并肝动-静脉分流的患者（慢速型分流21例，中速型分流40例，快速型分流36例），分别应用PVA-300、PVA-500及PVA-700行末梢性化疗栓塞，其中慢、中速型加用碘油化疗乳剂栓塞，快速型仅加用化疗药物。应用Kaplan-Meier法、Log-Rank检验进行生存分析，Cox比例风险模型进行多因素回归分析。结果 97例肝癌合并肝动-静脉分流的患者中位生存期为281 d，6、12、18个月生存率分别为67%、37.2%、14.2%。多因素分析结果显示：术前AFP≥400 ng/ml（HR=3.763，P=0.002）、门静脉癌栓形成（HR=2.669，P=0.021）及疾病进展（HR=2.55，P=0.039）为独立危险因素；而栓塞次数≥3次（HR=0.216，P=0.001）、分流完全及次全栓塞（HR=0.22，P=0.030）及采用综合治疗（HR=0.181，P＜0.001）为独立保护因素。结论 PVA联合碘油化疗药乳剂（或化疗药物）末梢性化疗栓塞肝癌合并肝动-静脉分流是一种可行、有效的方法。栓塞次数较多、分流完全及次全栓塞以及采用综合治疗的患者预后较好，而术前AFP高水平、门静脉癌栓形成及疾病进展为患者预后危险因素。

参考文献/References:

［1］ Ngan H, Peh WC. Arteriovenous shunting in hepatocellular carcinoma: its prevalence and clinical significance［J］. Clin Radiol, 1997, 52: 36-40.
［2］ 刘 圣， 施海彬， 杨正强， 等． α-氰基丙烯酸正丁酯栓塞治疗肝细胞癌并肝动脉-门静脉瘘的临床价值［J］． 中华放射学杂志， 2009， 43： 279-283．
［3］ 孙 磊， 施海彬， 刘 圣， 等． 肝细胞癌肝动脉门静脉分流形成的相关因素分析［J］． 介入放射学杂志， 2012， 21： 206-210．
［4］ Mei Q, Li Y. Transcatheter arterial embolization of hepatic arteriovenous shunts in patients with hepatocellular carcinoma［J］. Semin Intervent Radiol, 2012, 29: 237-240.
［5］ 李彦豪， 何晓峰， 陈 勇． 实用临床介入诊疗学图解［M］． 第3版． 北京： 科学出版社， 2012： 344-347．
［6］ Lencioni R, Llovet JM. Modified RECIST（mRECIST） assessment for hepatocellular carcinoma［J］. Semin Liver Dis, 2010, 30: 52-60.
［7］ Zhou WZ, Shi HB, Liu S, et al. Arterioportal shunts in patients with hepatocellular carcinoma treated using ethanol-soaked gelatin sponge: therapeutic effects and prognostic factors［J］. J Vasc Interv Radiol, 2015, 26: 223-230.
［8］ Maluccio MA, Covey AM, Porat LB, et al. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma［J］. J Vasc Interv Radiol, 2008, 19: 862-869.
［9］ 周卫忠， 刘 圣， 杨正强， 等． 氰基丙烯酸酯胶栓塞原发性肝细胞癌合并重度肝动脉门静脉瘘12例疗效分析［J］． 介入放射学杂志， 2013， 22： 641-645．
［10］ Kim YJ, Lee HG, Park JM, et al. Polyvinyl alcohol embolization adjuvant to oily chemoembolization in advanced hepatocellular carcinoma with arterioportal shunts［J］. Korean J Radiol, 2007, 8: 311-319.
［11］ Shi HB, Yang ZQ, Liu S, et al. Transarterial embolization with cyanoacrylate for severe arterioportal shunt complicated by hepatocellular carcinoma［J］. Cardiovasc Intervent Radiol, 2013, 36: 412-421.
［12］ Hu HT, Kim JH, Lee LS, et al. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort［J］. J Vasc Interv Radiol, 2011, 22: 917-923.
［13］ Vogl TJ, Nour-Eldin NE, Emad-Eldin S, et al. Portal vein thrombosis and arterioportal shunts: effects on tumor response after chemoembo-lization of hepatocellular carcinoma［J］. World J Gastroenterol, 2011, 17: 1267-1275.
［14］ Chern MC, Chuang VP, Liang CT, et al. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors［J］. J Vasc Interv Radiol, 2014, 25: 32-40.
［15］ 毕新宇， 阎 涛， 赵 宏， 等． 甲胎蛋白水平与肝细胞癌预后的相关性分析［J］． 中华医学杂志， 2014， 94： 2645-2649．
［16］ 欧阳墉， 欧阳雪晖． 肝内肝动脉-门静脉分流的研究进展［J］．医学影像学杂志， 2005， 15： 1019-1023．
［17］ Ni JY, Sun HL, Chen YT, et al. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma［J］. World J Gastroenterol, 2014, 20: 17483-17490.
［18］ Ni JY, Liu SS, Xu LF, et al. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma［J］. World J Gastroenterol, 2013, 19: 3872-3882.
［19］ 含 笑， 吕维富． 经肝动脉化疗栓塞联合射频消融治疗原发性肝癌远期疗效的荟萃分析［J］． 介入放射学杂志， 2013， 22： 387-391．
［20］ Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes［J］. Int J Radiat Oncol Biol Phys, 2012, 82: 2004-2011.
［21］ Oh D, Shin SW, Park HC, et al. Changes in arterioportal shunts in hepatocellular carcinoma patients with portal vein thrombosis who were treated with chemoembolization followed by radiotherapy［J］. Cancer Res Treat, 2015, 47: 251-258.
［22］ 陈 勇， 赵剑波， 曾庆乐， 等． 经皮穿刺瘤内注入碘油化疗药乳剂治疗原发性肝癌［J］． 中华普通外科杂志， 2009， 24： 992-995．
［23］ Chen J, Chen S, Xi W, et al. Transcatheter Arterial Chemoembo-lization and Chemotherapy plus Sorafenib in a Large Hepatocellular Carcinoma with Arterioportal Shunt［J］. Case reports in oncological medicine, 2014, 2014: 392403.
［24］ Chao Y, Chung YH, Han G, et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial［J］. Int J Cancer, 2015, 136: 1458-1467.
［25］ Berk V, Kaplan MA, Tonyali O, et al. Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology［J］. Asian Pac J Cancer Prev, 2013, 14: 7367-7369.
［26］ Liu L, Chen H, Wang M, et al. Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis［J］. PLoS One, 2014, 9: e91124.
［27］ Chan WS, Poon WL, Cho DH, et al. Transcatheter embolisation of intrahepatic arteriovenous shunts in patients with hepatocellular carcinoma［J］. Hong Kong Med J, 2010, 16: 48-55.
［28］ Yoshida K, Melake M, Oishi H, et al. Transvenous embolization of dural carotid cavernous fistulas: a series of 44 consecutive patients［J］. AJNR Am J Neuroradiol, 2010, 31: 651-655.

相似文献/References:

[1]方 瑜,龙清云,刘骏方,等.肝癌合并肝动脉-肝门静脉瘘介入治疗方式的探讨[J].介入放射学杂志,2010,(10):776.
　FANG Yu,LONG Qing-yun,LIU Jun-fang,et al.Exploration of interventional therapeutic pattern for hepatocellular carcinoma associated with hepatic arterioportal fistulae[J].journal interventional radiology,2010,(12):776.
[2]邱伟利,王成刚.肝动脉化疗栓塞治疗转移性肝癌25例分析[J].介入放射学杂志,1997,(03):146.
[3]李茂全.胃癌介入治疗的现状和研究进展[J].介入放射学杂志,1999,(01):54.
[4]张绪敬,程佩芳,董光,等.原发性肝癌经导管化疗、栓塞前后血中凝血酶原变化的研究[J].介入放射学杂志,1992,(01):33.
[5]周文群,刘子江,袁建华,等.动脉内顺铂微球碘化油与抗癌药物碘化油栓塞化疗对肝癌疗效的比较[J].介入放射学杂志,1992,(01):27.
[6]李茂全,颜志平,周康荣,等.中晚期肝癌根治术后介入放射学治疗的临床研究[J].介入放射学杂志,1994,(02):79.
[7]刘古燕,金琰,王树森,等.肠系膜下动脉化疗栓塞致肛门括约肌松驰一例[J].介入放射学杂志,1994,(03):180.
[8]俞进友,朱良志,夏曙祥,等.肝动栓塞治疗肝癌并发癌破裂二例[J].介入放射学杂志,1994,(04):188.
[9]陈雪萍,程永德.肝癌肝动脉化疗栓塞术后影响甲胎蛋白下降因素探讨[J].介入放射学杂志,1995,(02):73.
[10]郝楠馨,贾雨辰,陈庆华,等.甲氨蝶呤明胶微球经肝动脉灌注后近期毒性的实验研究[J].介入放射学杂志,1995,(03):154.

备注/Memo

备注/Memo:
（收稿日期：２０１5-０4-０8）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2015-12-24